BCL2 and lymphoma: From an epigenetic perspective, selected genetic subtypes of DLBCL might respond to targeting MYC activity with BET-bromodomain inhibitors, alone or in combination with BCL2 inhibition [249], and BET inhibition can repress PD-L1 expression and synergize with PD-1/PD-L1 blockade in mice bearing Myc-driven lymphomas [250].